Our present study perhaps supports a further avenue for in vivo and clinical trial of the food molecule, 4-(3,4-dihydroxyphenyl)-2-hydroxy-1H-phenalen-1-one to target BACE1 for any future scope to treat the AD along with viruses and cancer. This evidence concerns the gene BACE1 and cancer.